Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Duesseldorf, Germany.
Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Duesseldorf, Germany; Cardiovascular Research Institute Düsseldorf (CARID), Duesseldorf, Germany.
Pharmacol Ther. 2022 Dec;240:108230. doi: 10.1016/j.pharmthera.2022.108230. Epub 2022 Jun 10.
Cardiogenic shock is a clinical syndrome of impaired tissue perfusion caused by primary cardiac dysfunction and inadequate cardiac output. It represents one of the most lethal clinical conditions in intensive care medicine with mortality >40%. Management of different clinical presentations of cardiogenic shock includes guidance of cardiac preload, afterload, heart rate and contractility by differential pharmacological modulation of volume, systemic and pulmonary vascular resistance and cardiac output besides reversing the triggering cause. Data from large registries and randomized controlled trials on optimal diagnostic guidance as well as choice of pharmacological agents has accrued significantly in recent years. This state-of-the-art review summarizes the basic concepts of cardiogenic shock, the diagnostic work-up and currently available evidence and guideline recommendations on pharmacological treatment of cardiogenic shock.
心原性休克是一种由原发性心功能障碍和心输出量不足引起的组织灌注受损的临床综合征。它是重症监护医学中最致命的临床情况之一,死亡率>40%。心原性休克的不同临床表现的治疗包括通过对容量、全身和肺血管阻力以及心输出量的差异药理学调节来指导心脏前负荷、后负荷和心率以及收缩性,此外还要逆转触发原因。近年来,关于最佳诊断指导以及药物选择的大型注册研究和随机对照试验的数据有了显著积累。本综述总结了心原性休克的基本概念、诊断方法以及目前关于心原性休克药物治疗的循证医学证据和指南建议。